SeaCrest Wealth Management LLC Invests $212,000 in iRhythm Technologies, Inc. (NASDAQ:IRTC)

SeaCrest Wealth Management LLC bought a new stake in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 2,030 shares of the company's stock, valued at approximately $212,000.

Other hedge funds have also recently bought and sold shares of the company. Van ECK Associates Corp increased its position in shares of iRhythm Technologies by 41.3% during the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company's stock valued at $50,000 after purchasing an additional 162 shares during the period. Raiffeisen Bank International AG acquired a new stake in iRhythm Technologies during the fourth quarter worth $60,000. Xponance Inc. acquired a new stake in iRhythm Technologies during the fourth quarter worth $203,000. LPL Financial LLC bought a new stake in iRhythm Technologies in the 4th quarter valued at $243,000. Finally, Versor Investments LP acquired a new position in shares of iRhythm Technologies in the 4th quarter valued at $251,000.

iRhythm Technologies Price Performance

iRhythm Technologies stock traded down $1.90 on Thursday, reaching $145.48. The company's stock had a trading volume of 432,838 shares, compared to its average volume of 482,076. The business's fifty day moving average price is $124.95 and its 200 day moving average price is $108.88. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. The company has a market cap of $4.64 billion, a price-to-earnings ratio of -39.97 and a beta of 1.40. iRhythm Technologies, Inc. has a twelve month low of $55.92 and a twelve month high of $150.00.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.06). The business had revenue of $158.68 million during the quarter, compared to the consensus estimate of $153.39 million. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The business's quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.23) earnings per share. Equities analysts expect that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IRTC. Truist Financial lifted their target price on shares of iRhythm Technologies from $111.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Canaccord Genuity Group dropped their target price on iRhythm Technologies from $152.00 to $139.00 and set a "buy" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group boosted their price target on iRhythm Technologies from $91.00 to $124.00 and gave the company a "neutral" rating in a research note on Monday, February 24th. Robert W. Baird upped their price target on iRhythm Technologies from $133.00 to $150.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Wall Street Zen cut iRhythm Technologies from a "hold" rating to a "sell" rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, iRhythm Technologies presently has an average rating of "Moderate Buy" and an average price target of $136.45.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.